1-4 of 4
Dan Rudin
Close
Sort by
Journal Articles

BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer

Barbara A Konkle, Amy Shapiro, Doris Quon, Janice Staber, Takashi Suzuki, MD PhD, Stacey Poloskey, Kara Rice, Suresh Katragadda, Dan Rudin, Joachim Fruebis
Journal: Blood
Blood (2018) 132 (Supplement 1): 636.
https://doi.org/10.1182/blood-2018-99-113575
Published: 2018
Journal Articles

B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B

Margaret Ragni, Roshni Kulkarni, K. John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Kathelijn Fischer, Johnny Mahlangu, Amy Shapiro, Beatrice Nolan, Johannes Oldenburg, Tadashi Matsushita, Annemieke Willemze, Huixing Yuan, Dan Rudin
Journal: Blood
Blood (2018) 132 (Supplement 1): 1214.
https://doi.org/10.1182/blood-2018-99-110100
Published: 2018
Journal Articles

ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A

Beatrice Nolan, Johnny Mahlangu, Guy Young, Barbara A Konkle, K. John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Johannes Oldenburg, MD PhD, Keiji Nogami, MDPhD, Nikola Tripkovic, Huixing Yuan, Dan Rudin
Journal: Blood
Blood (2018) 132 (Supplement 1): 1192.
https://doi.org/10.1182/blood-2018-99-118586
Published: 2018
Journal Articles

A Phase 1, Open Label Study To Evaluate The Drug Interaction Potential With Ketoconazole and The Effect Of Food On The Plasma Pharmacokinetics Of The Smoothened Inhibitor PF-04449913

M.Naveed Shaik, PhD, Robert R LaBadie, MPH, Dan Rudin, MD, Wendy J. Levin, MD, MS
Journal: Blood
Blood (2013) 122 (21): 3857.
https://doi.org/10.1182/blood.V122.21.3857.3857
Published: 2013